Display options
Cite
Lane AC, Nichols JD, Steel ND, et al. Determination of idazoxan in plasma by radioreceptor assay. J Pharm Biomed Anal. 1988;6(6):787-92doi: 10.1016/0731-7085(88)80092-x.
Lane, A. C., Nichols, J. D., Steel, N. D., Sugden, K., & Walter, D. S. (1988). Determination of idazoxan in plasma by radioreceptor assay. Journal of pharmaceutical and biomedical analysis, 6(6), 787-92. https://doi.org/10.1016/0731-7085(88)80092-x
Lane, A C, et al. "Determination of idazoxan in plasma by radioreceptor assay." Journal of pharmaceutical and biomedical analysis vol. 6,6 (1988): 787-92. doi: https://doi.org/10.1016/0731-7085(88)80092-x
Lane AC, Nichols JD, Steel ND, Sugden K, Walter DS. Determination of idazoxan in plasma by radioreceptor assay. J Pharm Biomed Anal. 1988;6(6):787-92. doi: 10.1016/0731-7085(88)80092-x. PMID: 16867344.
Copy Download .nbib Format: NLM
Share it on

J Pharm Biomed Anal. 1988;6(6):787-92. doi: 10.1016/0731-7085(88)80092-x.

Determination of idazoxan in plasma by radioreceptor assay.

Journal of pharmaceutical and biomedical analysis

A C Lane, J D Nichols, N D Steel, K Sugden, D S Walter

Affiliations

  1. Reckitt and Colman plc, Pharmaceutical Division, Dansom Lane, Kingston Upon Hull, HU8 7DS, UK.

PMID: 16867344 DOI: 10.1016/0731-7085(88)80092-x

Abstract

A radioreceptor assay to determine the plasma concentration of idazoxan, a potent, highly selective antagonist for the alpha(2)-adrenoreceptor, is described. The assay is based upon a technique in which plasma extracts containing idazoxan compete with radiolabelled ligand for binding sites on receptor-rich tissue prepared from beef brain cortex. Using a logistic data-fit the limit of detection is of the order of 1 ng ml(-1) and represents a 10-fold increase in sensitivity over that from an established HPLC procedure. Comparison of human plasma data from the two assays indicates a correlation coefficient of 0.92 (N = 27) although the chromatographic method gave consistently higher values than the binding assay. The binding assay requires no sample extraction or pretreatment of plasma and its accuracy, precision and inherent specificity are such that the method represents a useful alternative to HPLC for therapeutic drug monitoring.

Publication Types